Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Benefit seen with multi-herbal product Yi-Gan San in vascular dementia patients

Jan. 19, 2009

Intra-Cellular reports top-line phase II ITI-007 results in insomnia

Jan. 19, 2009

Kyowa Hakko Kirin to further evaluate KW-6002 in Japan

Jan. 16, 2009

Savella approved by the FDA for the management of fibromyalgia

Jan. 16, 2009

FDA issues complete response letter for Schering-Plough's NDA for Saphris

Jan. 16, 2009

Sygnis presents update on preparations for phase II efficacy trial of AX-200 in acute stroke

Jan. 16, 2009

Akela achieves milestone payment from Janssen related to phase III study of Taifun

Jan. 16, 2009

Jazz completes enrollment in phase III clinical trial of JZP-6 for fibromyalgia

Jan. 16, 2009

EVP-6124 shows improvement in cognition biomarkers in schizophrenia

Jan. 16, 2009

AcelRx reports positive results from NanoTab trial in pain and anxiety

Jan. 16, 2009

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 7, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...